CGT6297

· Cogent Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CGT6297, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors [Phase 1]